HIDDEN OVERHEAD COSTS: IS CANADA’S SYSTEM REALLY LESS EXPENSIVE? Health Affairs, Spring 1992 by Patricia M. Danzon
نویسنده
چکیده
Prologue: Canada’s provincial health insurance scheme is a source of endless fascination to policymakers advocating health system reform. Whether one is an advocate or a or a detractor of Canada’s plan us a model for the United States, an important issue that engages the antagonists is how much it costs to operate compared with America’s pluralistic and mostly private health insurance approach. The measurement of such administrative expenses by various parties has brought to policymakers attention the trade-offs that exist whichever way a system is organized. However, there is no consensus on the nature and magnitude of these trade-offs. In this paper, Patricia Danzon, the Celia Moh Professor of Health Care Systems and Insurance at the University of Pennsylvania’s Wharton School, examines the overhead costs of alternative health care systems, asserting that existing comparisons are grossly misleading. She compares overhead costs under monopoly public insurance and competitive private insurance markets in general but draws on actual experience in Canada and the United States for empirical evidence. Danzon concludes that private health insurance has built-in incentives to minimize its total overhead costs, while public health insurance constrains total budgets but ignores real social costs, including the time patients must wait for treatment and the lost productivity that results. Danzon holds a doctorate in economics from the University of Chicago. She turned to health economics while working at The RAND Corporation from 1973 to 1979. Danzon is the author of a book entitled Medical Malpractice: Theory, Evidence, and Public Policy (Harvard University Press). She also coauthored a paper published in Health Affairs (Spring 1991) entitled “A Plan for ‘Responsible National Health Insurance’.”
منابع مشابه
Hidden overhead costs: is Canada's system really less expensive?
Prologue: Canada’s provincial health insurance scheme is a source of endless fascination to policymakers advocating health system reform. Whether one is an advocate or a or a detractor of Canada’s plan us a model for the United States, an important issue that engages the antagonists is how much it costs to operate compared with America’s pluralistic and mostly private health insurance approach....
متن کاملPrices and availability of pharmaceuticals: evidence from nine countries.
This study compares average price levels for pharmaceuticals in eight countries--Canada, Chile, France, Germany, Italy, Japan, Mexico, and the United Kingdom--relative to the United States. Our most comprehensive indexes, adjusted for U.S. manufacturer discounts, show Japan's prices to be higher than U.S. prices, and other countries' prices ranging from 6 percent to 33 percent lower than U.S. p...
متن کاملCompensation for Occupational Disease: Evaluating the Options
This paper evaluates alternative rules of liability and compensation for occupational disease. The criterion applied is minimization of the sum of the costs associated with occupational disease, disease prevention, uninsured risk costs, and litigation and insurance overhead or transaction costs. Options considered include the workers' compensation system, the tort system, first party insurance,...
متن کاملA plan for 'responsible national health insurance'.
Prologue: In December 1975, at a hearing convened by a House health panel, Chairman Paul Rogers declared: “Today the Subcommittee on Health and the Environment begins its consideration of national health insurance–a concept which was articulated more than 25 years ago by President Truman and one which, as health care costs spiral and as more and more gaps in health care coverage are identified,...
متن کاملNber Working Paper Series Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand
This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals -Germany, the Netherlands, and New Zealand -and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insur...
متن کامل